Last Updated: 17 Oct 2024
Executive Summary
Aditxt Inc. (ADTX) is a clinical-stage biopharmaceutical company focused on developing and commercializing cell-based immunotherapies for the treatment of cancer. The company's lead product candidate, ADXS-NEO, is a personalized immunotherapy that uses the patient's own immune cells to target and destroy cancer cells.
Company Overview
Aditxt was founded in 2008 and is headquartered in Loma Linda, California. The company has a team of experienced scientists and executives with a track record of success in the biopharmaceutical industry. Aditxt's mission is to develop innovative cell-based immunotherapies that can improve the lives of cancer patients.
Fundamental Analysis
Revenue: Aditxt generated revenue of $329,740 in the twelve months ended June 30, 2024, a decrease of 0.8% year-over-year.
Gross Profit: The company's gross profit was $166,940 in the twelve months ended June 30, 2024, a decrease of 1.2% year-over-year.
Net Loss: Aditxt reported a net loss of $33,094,198 in the twelve months ended June 30, 2024, compared to a net loss of $27,871,000 in the same period last year.
EPS: The company's diluted EPS was -$1,375.2 in the twelve months ended June 30, 2024, compared to -$1,156.1 in the same period last year.
Book Value: Aditxt's book value per share was $131.74 as of June 30, 2024.
Technical Analysis
52-Week High: $428.00
52-Week Low: $1.07
50-Day Moving Average: $22.21
200-Day Moving Average: $90.50
Aditxt's stock price has been in a downtrend since reaching a 52-week high of $428.00 in January 2023. The stock is currently trading below its 50-day and 200-day moving averages.
Short Term Outlook
Aditxt's short-term outlook is uncertain. The company's stock price has been volatile in recent months and is currently trading near its 52-week low. Aditxt is expected to release its next quarterly earnings report in August 2024. The company's earnings report could provide more insight into its financial performance and future prospects.
Long Term Outlook
Aditxt's long-term outlook is promising. The company's lead product candidate, ADXS-NEO, has shown promising results in clinical trials. If ADXS-NEO is approved by the FDA, it could be a major commercial success for Aditxt. The company also has a pipeline of other promising cell-based immunotherapies in development.
Analyst Recommendations
The majority of analysts who cover Aditxt rate the stock as a "Hold." The average analyst target price for Aditxt is $61.00.
